JPH05306221A - Composition useful as washing liquid for intestinal canal and the washing liquid for intestinal canal - Google Patents
Composition useful as washing liquid for intestinal canal and the washing liquid for intestinal canalInfo
- Publication number
- JPH05306221A JPH05306221A JP13204292A JP13204292A JPH05306221A JP H05306221 A JPH05306221 A JP H05306221A JP 13204292 A JP13204292 A JP 13204292A JP 13204292 A JP13204292 A JP 13204292A JP H05306221 A JPH05306221 A JP H05306221A
- Authority
- JP
- Japan
- Prior art keywords
- washing liquid
- magnesium citrate
- intestinal
- aqueous solution
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 239000007788 liquid Substances 0.000 title abstract description 12
- 238000005406 washing Methods 0.000 title abstract description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims abstract description 27
- 229960005336 magnesium citrate Drugs 0.000 claims abstract description 22
- 239000004337 magnesium citrate Substances 0.000 claims abstract description 22
- 235000002538 magnesium citrate Nutrition 0.000 claims abstract description 22
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims abstract description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000007864 aqueous solution Substances 0.000 claims abstract description 10
- 230000003204 osmotic effect Effects 0.000 claims abstract description 10
- 239000011780 sodium chloride Substances 0.000 claims abstract description 10
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 4
- 239000012530 fluid Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000243 solution Substances 0.000 description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000003792 electrolyte Substances 0.000 description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 239000000644 isotonic solution Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229910001414 potassium ion Inorganic materials 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- KVNZYYKJJVJHBV-UHFFFAOYSA-L magnesium;hydron;2-hydroxypropane-1,2,3-tricarboxylate;pentahydrate Chemical compound O.O.O.O.O.[Mg+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O KVNZYYKJJVJHBV-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000035923 taste sensation Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、腸管洗浄液及び、水に
溶かして該腸管洗浄液を調製するための腸管洗浄液用組
成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an intestinal lavage fluid and a composition for intestinal lavage fluid which is dissolved in water to prepare the intestinal lavage fluid.
【0002】[0002]
【従来の技術】腸管の洗浄による清浄化は、注腸X線検
査や大腸内視鏡検査において診断の正確さを確保するた
めにも、また、腸切除術等において術後の感染症を予防
するためにも、不可欠の前処置である。近年、大腸疾患
の増加により腸管洗浄は医療における実施頻度と重要性
をいよいよ増しつつある。2. Description of the Related Art Cleaning of the intestinal tract is necessary to ensure the accuracy of diagnosis in enema X-ray examination and colonoscopy, and to prevent postoperative infections in enterectomy. This is also an indispensable pretreatment. In recent years, with the increase in colorectal diseases, intestinal lavage is becoming more and more important in medical practice.
【0003】腸管洗浄には、古くは洗腸を行う方法が一
般的であったが、洗浄液の十分な排出という面で難点を
有し、造影剤の希釈によって微細病変の診断を困難にす
るという問題があった。その後、ブラウンによる洗腸を
行わない前処置法の報告〔Brown, G.R.: Univ. Michiga
n M Bull 27: 225-230, 1961〕以降、経口的に摂取した
大量の水分によって腸管を洗浄する種々の方法が開発さ
れてきた。In the intestinal tract lavage, a method of performing an intestinal lavage was generally used in old days, but it has a drawback in that the lavage fluid is sufficiently discharged, and it is difficult to diagnose a microscopic lesion by diluting the contrast medium. There was a problem. After that, Brown reported a pretreatment method without intestinal washing [Brown, GR: Univ. Michiga
n M Bull 27: 225-230, 1961] since then, various methods for cleaning the intestinal tract with a large amount of water taken orally have been developed.
【0004】ブラウンによる方法は、検査前日に水分を
大量に摂取させた後、腸管からの水分吸収を阻害する塩
類下剤を投与するとともに、接触性下剤によって腸管の
蠕動運動を亢進させて腸内容物を一気に洗い流すことを
特徴とする。In the method by Brown, a large amount of water was ingested on the day before the test, and then a salt laxative that inhibits water absorption from the intestinal tract was administered, and the peristaltic movement of the intestinal tract was enhanced by a contact laxative to intestinal contents. The feature is to wash away all at once.
【0005】しかしブラウンによる方法では右半結腸の
清浄化が困難であることや、大量の水分摂取が心不全や
腎障害のある患者に与え得る悪影響への懸念から、その
後、生理食塩水をベースとした電解質水溶液の大量服用
法〔J. Hewitt, et al., Lancet, 2: 337(1973〕や、マ
ンニトール添加電解質溶液〔Minervini, S. et al.,Gu
t, 20: A452, 1979 〕が提案されたが、前者は相当量の
水分吸収を起こすため、後者はマンニトールの腸内細菌
による分解で生じた水素やメタンガス等による術中の腸
内爆発事故のため、一般に使用されていない。However, because of the difficulty of clearing the right hemicolon by the method of Brown and the fear that a large amount of water intake may have an adverse effect on patients with heart failure and renal failure, a saline-based method was used thereafter. Mass dose of the above-mentioned electrolyte aqueous solution [J. Hewitt, et al., Lancet, 2: 337 (1973)] and mannitol-added electrolyte solution [Minervini, S. et al., Gu
t, 20: A452, 1979] was proposed, but the former causes a considerable amount of water absorption, and the latter causes an intraoperative intestinal explosion accident due to hydrogen or methane gas generated by decomposition of mannitol by intestinal bacteria. , Not commonly used.
【0006】その後、ポリエチレングリコールと電解質
を主成分とした経口腸管洗浄液(以下「PEG液」とい
う。)が開発され普及しつつある〔Davis, G. R. et a
l., Gastroenterology,78, 991-995, 1980 〕。PEG
液による洗浄効果は高いものであるが、やはり大量(約
2L以上)の洗浄液を服用するものであることから、広
く用いられるためには服用の容易なことが必要である。After that, an oral intestinal lavage solution (hereinafter referred to as "PEG solution") containing polyethylene glycol and an electrolyte as main components was developed and is becoming popular [Davis, GR et a.
L., Gastroenterology, 78, 991-995, 1980]. PEG
Although the cleaning effect by the liquid is high, since a large amount (about 2 L or more) of cleaning liquid is also taken, it is necessary to be easy to take for widespread use.
【0007】しかし、PEG液は多量に服用するには味
覚上かなりの難点があり、服用困難や服用後の吐き気等
患者に苦痛を与えることから、該洗浄液を広く一般的に
使用するには問題がある。However, the PEG solution has a considerable difficulty in taste when it is taken in a large amount, and causes pain to patients such as difficulty in taking it and nausea after taking it. There is.
【0008】このため最近では、PEG液と同等又はそ
れ以上の効果を有する腸管洗浄液として、クエン酸マグ
ネシウム等張液の服用が試みられている。クエン酸マグ
ネシウムは、腸管からは殆ど吸収されず、体液と等張と
なるよう水に溶解した液を1800至2700mLを経
口投与することにより、実質上、水分の体液側への吸収
や体液側からの脱水を伴うことなく、腸管内を短時間に
且つPEG液と同等又はそれ以上の優れた効果をもって
洗浄することができることが報告されている〔基礎と臨
床、第24巻第14号第246 −365 頁(1990)〕。しかもク
エン酸マグネシウム液は味覚の点でPEG液よりはるか
に優れており、そのため服用が容易で服用後の吐き気も
生じにくい〔同〕ため、広く一般に用いる上で好ましい
洗浄液である。Therefore, in recent years, it has been attempted to take an isotonic solution of magnesium citrate as an intestinal lavage solution having an effect equal to or higher than that of the PEG solution. Magnesium citrate is hardly absorbed from the intestinal tract, but by orally administering 1800 to 2700 mL of a solution dissolved in water so as to be isotonic with the body fluid, it is substantially absorbed from the body fluid side or from the body fluid side. It has been reported that the intestinal tract can be washed in a short time and with an excellent effect equal to or higher than that of the PEG solution without being dehydrated (basic and clinical, Vol. 24, No. 14, 246- 365 (1990)]. Moreover, the magnesium citrate solution is far superior to the PEG solution in terms of taste, and therefore is easy to take and is less likely to cause nausea after taking [the same], and is therefore a preferred washing solution for general use.
【0009】なお本明細書において「クエン酸マグネシ
ウム」とは、クエン酸一水素マグネシウム5水塩(Mg
HC6 H5 O7 ・5H2 O)をいう。In the present specification, "magnesium citrate" means magnesium monohydrogen citrate pentahydrate (Mg
HC 6 H 5 O 7 · 5H 2 O) refers to.
【0010】しかしながら、服用により必然的に引き起
こされる激しい下痢のためと考えられる体内の電解質バ
ランスの変動が、クエン酸マグネシウム等張液の副作用
として見出されており、心、肺、腎等の機能障害等ため
電解質代謝に問題のある患者に使用するには潜在的危険
を伴う〔同〕。However, a change in the electrolyte balance in the body, which is considered to be caused by severe diarrhea inevitably caused by taking the drug, has been found as a side effect of isotonic solution of magnesium citrate, and functions of the heart, lungs, kidneys, etc. There is a potential danger when used in patients with electrolyte metabolism problems due to disorders, etc. [Same as above].
【0011】クエン酸マグネシウム等張液による電解質
バランスの変動は、主としてカリウムイオン及び塩素イ
オンの減少であり、これを防止する目的で、塩化カリウ
ム錠を同時に服用することが試みられ一定の成果をあげ
た。その一方、クエン酸マグネシウム等張液に塩化カリ
ウムを直接添加すると「何ともいえないまずい味」とな
るため、直接添加は実際上行い得ないことが判明してお
り(同)、腸管洗浄液と塩化カリウム錠との服用が別個
に行われている。このような方法は煩雑であるのみなら
ず、塩化カリウム錠服用の失念等に起因する副作用の発
生の可能性を潜在的にはらむものであり、何らかの改善
を必要とするものであった。The change in the electrolyte balance due to the isotonic solution of magnesium citrate is mainly a decrease in potassium ion and chloride ion, and in order to prevent this, simultaneous administration of potassium chloride tablets has been tried and some results have been achieved. It was On the other hand, when potassium chloride is directly added to an isotonic solution of magnesium citrate, it becomes “a bad taste”, and it has been proved that direct addition cannot be practically performed (the same). It is taken separately from the tablets. Such a method is not only complicated, but it potentially involves the possibility of side effects due to forgetfulness of taking potassium chloride tablets, etc., and requires some improvement.
【0012】[0012]
【発明が解決しようとする課題】本発明は、かかる状況
の下において、クエン酸マグネシウム等張液と同等の優
れた洗浄効果を有し、且つ患者の電解質バランスに与え
る副作用を防止し、しかも味覚の点で服用し易い腸管洗
浄液及び該腸管洗浄液用組成物を提供することを目的と
する。Under the circumstances, the present invention has an excellent cleaning effect equivalent to that of magnesium citrate isotonic solution, prevents side effects on the electrolyte balance of the patient, and has a taste sensation. In view of the above, it is an object of the present invention to provide an intestinal lavage fluid that is easy to take and a composition for the intestinal lavage fluid.
【0013】[0013]
【課題を解決するための手段】本発明者は、クエン酸マ
グネシウムをベースとする種々の組成物を検討した結
果、クエン酸マグネシウムを主体としこれに塩化ナトリ
ウム、水酸化カリウム、及び所望により白糖その他の甘
味を有する糖類を一定範囲の比率に含有してなる体液と
等張の水溶液が上記の目的に合致することを見出し、本
発明を完成した。As a result of studying various compositions based on magnesium citrate, the present inventor has found that magnesium citrate is the main component of which sodium chloride, potassium hydroxide, and optionally sucrose and other The present invention has been completed by finding that a body fluid containing isotonic sugar in a ratio of a certain range and an isotonic aqueous solution meet the above object.
【0014】すなわち本発明は、900mLあたりクエ
ン酸マグネシウム32.3乃至35.7gを含有し、更
に塩化ナトリウム、水酸化カリウム及び糖類を浸透圧が
最終的に290乃至310mOsm/Lとなる濃度に含
有してなる水溶液であることを特徴とする腸管洗浄液で
ある。かかる浸透圧とするために好ましい各成分の量は
例えば、塩化ナトリウム4.8乃至5.4mmol、水
酸化カリウム8.5乃至9.3mmol及び糖類10.
7乃至2.1gである。That is, the present invention contains 32.3 to 35.7 g of magnesium citrate per 900 mL, and further contains sodium chloride, potassium hydroxide and saccharide in a concentration such that the osmotic pressure finally becomes 290 to 310 mOsm / L. The intestinal lavage fluid is an aqueous solution obtained by Preferred amounts of each component for achieving such an osmotic pressure are, for example, sodium chloride 4.8 to 5.4 mmol, potassium hydroxide 8.5 to 9.3 mmol, and sugar 10.
7 to 2.1 g.
【0015】更に本発明は、クエン酸マグネシウムを含
有し、該クエン酸マグネシウム32.3乃至35.7g
あたり塩化ナトリウム4.8乃至5.4mmol、水酸
化カリウム8.5乃至9.3mmol及び糖類10.7
乃至2.1gを更に含有することを特徴とする、水に溶
解して浸透圧290乃至310mOsm/Lの水溶液と
して使用するための腸管洗浄液用組成物である。Further, the present invention contains magnesium citrate, and the magnesium citrate 32.3 to 35.7 g
Sodium chloride 4.8 to 5.4 mmol, potassium hydroxide 8.5 to 9.3 mmol, and sugar 10.7
The composition for intestinal tract washing liquid for use as an aqueous solution having an osmotic pressure of 290 to 310 mOsm / L after being dissolved in water, further containing 0.1 to 2.1 g.
【0016】上記において糖類とは、甘味を有する糖類
例えば白糖、麦芽糖、ブドウ糖、果糖、転化糖等を含
む。最も簡便には白糖が使用される。In the above, sugars include sugars having sweetness, such as sucrose, maltose, glucose, fructose and invert sugar. Most conveniently, white sugar is used.
【0017】このような組成物の例えば50gを水に溶
解して全量900mLとすることにより、目的とする浸
透圧290乃至310mOsm/Lの範囲に入る腸管洗
浄液を容易に製造することができる。By dissolving, for example, 50 g of such a composition in water to a total amount of 900 mL, a desired intestinal tract washing solution having an osmotic pressure of 290 to 310 mOsm / L can be easily produced.
【0018】290乃至310mOsmol/Lの範囲
の浸透圧は体液と実質的に等張であり、腸管から体液側
への水分の吸収や体液側からの脱水のいずれも生じるこ
となく腸管洗浄液として安全且つ有効に使用することが
できる浸透圧範囲である。その結果、本発明の腸管洗浄
液は現行のクエン酸マグネシウム等張液と腸管洗浄効果
において同等である。The osmotic pressure in the range of 290 to 310 mOsmol / L is substantially isotonic with the body fluid, and is safe as an intestinal lavage fluid without causing any absorption of water from the intestinal tract to the body fluid side or dehydration from the body fluid side. It is an osmotic pressure range that can be effectively used. As a result, the intestinal lavage fluid of the present invention is equivalent in intestinal lavage effect to the current isotonic magnesium citrate solution.
【0019】また、本発明の腸管洗浄液によれば、現行
のクエン酸マグネシウム等張液に認められるような患者
の電解質バランスの変動を防止することができる。この
ため、本発明の腸管洗浄液は心、肺、腎等の機能障害等
のため電解質代謝に問題のある患者においても安心して
使用することができ、従来のクエン酸マグネシウム等張
液のように、塩化カリウム錠等を別途に服用する必要が
ない。Further, according to the intestinal lavage fluid of the present invention, it is possible to prevent the fluctuation of the electrolyte balance of the patient, which is observed in the current isotonic magnesium citrate solution. Therefore, the intestinal lavage fluid of the present invention can be safely used even in patients with problems in electrolyte metabolism due to functional disorders such as heart, lung, and kidney, and like conventional magnesium citrate isotonic solution, There is no need to take potassium chloride tablets etc. separately.
【0020】更に、患者の電解質バランスの変動防止の
ためにカリウムイオン等を含有しているにも拘わらず
「何ともいえないまずい味」の発生が防止され、本発明
の組成によれば現行のクエン酸マグネシウム等張液と同
様に味覚上優れた、服用し易い腸管洗浄液が提供され
る。Further, in order to prevent a change in the electrolyte balance of the patient, the occurrence of "a bad taste that cannot be said" is prevented even though it contains potassium ions and the like. Provided is an intestinal lavage liquid which is as tasty as the isotonic liquid of magnesium acid and is easy to take.
【0021】本発明の腸管洗浄液用組成物の製造は、例
えば次のようにして行うことができる。すなわち、先ず
炭酸マグネシウムを水に分散させ、これにクエン酸を加
えて溶解し、溶液に所定量の水酸化カリウムと塩化ナト
リウムの水溶液を添加攪拌した後、溶液を乾燥して粉末
化することにより得られる。糖類は例えば、こうして得
られた粉末に添加することによって組成物に含ませるこ
とができる。The intestinal tract washing composition of the present invention can be produced, for example, as follows. That is, first, magnesium carbonate is dispersed in water, citric acid is added to and dissolved in this, and a predetermined amount of an aqueous solution of potassium hydroxide and sodium chloride is added and stirred, and then the solution is dried and powdered. can get. Sugars can be included in the composition, for example, by adding to the powder thus obtained.
【0022】得られた混合粉末は、適宜の容器に包装し
て使用に供する。例えば、溶解に使用する一定の水量
(例えば900mL)を表示した包装に体液と等張とな
るに必要な分量ずつ分包することによって、用時溶解し
て使用するに便利な製剤とすることができる。The obtained mixed powder is packaged in an appropriate container for use. For example, a certain amount of water used for dissolution (for example, 900 mL) may be packaged in an amount corresponding to the amount necessary to make the body fluid isotonic in a labeled package, thereby making it a convenient formulation to be dissolved before use. it can.
【0023】次に典型的な一実施例を記すが、本発明は
該実施例の詳細に限定されるものではない。Next, an exemplary embodiment will be described, but the present invention is not limited to the details of the embodiment.
【実施例】精製水480Lに炭酸マグネシウム(日局
品)86.5kgを分散させた後、クエン酸(日局品)
184.0kgを徐々に加えてほぼ透明な液になるまで
加温する。冷後、精製水を加えて640Lとする。この
液にクエン酸21.0kgを加えて溶かし、これに水酸
化カリウム4.0kgと塩化ナトリウム2.4kgとを
予め水に溶解した液を加え、混合する。混合液を乾燥し
て粉末化し、乾燥品290kgを得る。得られた粉末に
白糖102.8kgを加え、混合機にて混合し、均一な
混合物とすることにより腸管洗浄液用組成物を得る。こ
れを自動充填機により1包50g(900mL用)ずつ
充填する。本製剤1包50gを水に溶解し900mLと
したものは浸透圧約300mOsm/Lであり、またカ
リウムイオン、塩素イオン等の含有にも拘わらず、現行
のクエン酸マグネシウム等張液の味覚を損なうことな
く、すなわちこれと同等の優れた味覚を保っており、腸
管洗浄液として不可避の大量服用に適したものであるこ
とが確認された。[Example] After dispersing 86.5 kg of magnesium carbonate (JPN product) in 480 L of purified water, citric acid (JPN product)
Gradually add 184.0 kg and heat until a nearly transparent liquid is obtained. After cooling, add purified water to make 640 L. To this solution is added 21.0 kg of citric acid to dissolve it, and to this is added a solution prepared by previously dissolving 4.0 kg of potassium hydroxide and 2.4 kg of sodium chloride in water, and mixed. The mixed solution is dried and powdered to obtain 290 kg of a dried product. 102.8 kg of sucrose was added to the obtained powder and mixed with a mixer to obtain a uniform mixture, thereby obtaining a composition for intestinal lavage fluid. This is filled with 50 g (for 900 mL) per packet by an automatic filling machine. A 50 mL portion of this preparation dissolved in water to make 900 mL has an osmotic pressure of about 300 mOsm / L, and the taste of the current isotonic solution of magnesium citrate is impaired despite the presence of potassium ion, chloride ion, etc. That is, it was confirmed that it was excellent, that is, it had an excellent taste equivalent to this, and that it was suitable as an intestinal lavage liquid for inevitable large dose administration.
Claims (2)
32.3乃至35.7g含有し、更に塩化ナトリウム、
水酸化カリウム及び糖類を浸透圧が最終的に290乃至
310mOsm/Lとなる濃度に含有してなる水溶液で
あることを特徴とする腸管洗浄液。1. 900 mL of magnesium citrate is contained in an amount of 32.3 to 35.7 g, and sodium chloride is further added,
An intestinal lavage fluid, which is an aqueous solution containing potassium hydroxide and saccharide in a concentration such that the osmotic pressure finally becomes 290 to 310 mOsm / L.
酸マグネシウムの32.3乃至35.7gあたり塩化ナ
トリウム4.8乃至5.4mmol、水酸化カリウム
8.5乃至9.3mmol及び糖類10.7乃至2.1
gを更に含有することを特徴とする、水に溶解して浸透
圧290乃至310mOsm/Lの水溶液として使用す
るための腸管洗浄液用組成物。2. Containing magnesium citrate, and 4.8 to 5.4 mmol of sodium chloride, 8.5 to 9.3 mmol of potassium hydroxide and 10.7 saccharide per 32.3 to 35.7 g of the magnesium citrate. To 2.1
A composition for intestinal lavage fluid, which further contains g, for use as an aqueous solution having an osmotic pressure of 290 to 310 mOsm / L by being dissolved in water.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4132042A JP3047143B2 (en) | 1992-04-24 | 1992-04-24 | Composition for intestinal lavage and intestinal lavage |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4132042A JP3047143B2 (en) | 1992-04-24 | 1992-04-24 | Composition for intestinal lavage and intestinal lavage |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05306221A true JPH05306221A (en) | 1993-11-19 |
JP3047143B2 JP3047143B2 (en) | 2000-05-29 |
Family
ID=15072156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4132042A Expired - Fee Related JP3047143B2 (en) | 1992-04-24 | 1992-04-24 | Composition for intestinal lavage and intestinal lavage |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3047143B2 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002265372A (en) * | 2001-03-07 | 2002-09-18 | Shimizu Pharmaceutical Co Ltd | Intestinal tract-cleaning agent |
WO2003074061A1 (en) * | 2002-03-04 | 2003-09-12 | Borody Thomas J | Electrolyte purgative |
JP2005507407A (en) * | 2001-10-29 | 2005-03-17 | 清水製薬株式会社 | Intestinal cleansing preparation |
WO2011136336A1 (en) | 2010-04-30 | 2011-11-03 | 味の素株式会社 | Liquid preparation for oral administration which can be used in ct colonography, and composition for imaging of digestive tract |
WO2012046847A1 (en) | 2010-10-08 | 2012-04-12 | 味の素株式会社 | Liquid preparation for oral administration which can be used in ct colonography, and composition for imaging digestive tract |
JP2015038127A (en) * | 2009-06-03 | 2015-02-26 | アプタリス ファーマ ユーエス,インコーポレイテッド | L-sugar colon cleansing agent and uses thereof |
US9308226B2 (en) | 2010-08-04 | 2016-04-12 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US9408872B2 (en) | 2000-07-25 | 2016-08-09 | Crestovo Llc | Probiotic recolonisation therapy |
US9649343B2 (en) | 2011-03-09 | 2017-05-16 | National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) | Compositions and methods for transplantation of colon microbiota |
US9901603B2 (en) | 2015-05-14 | 2018-02-27 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
US10092573B2 (en) | 2010-12-13 | 2018-10-09 | Salix Pharmaceuticals, Inc. | Gastric and colonic formulations and methods for making and using them |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US10195235B2 (en) | 2016-08-03 | 2019-02-05 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
US11202808B2 (en) | 2015-05-22 | 2021-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
US11357801B2 (en) | 2016-06-15 | 2022-06-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
US11542560B2 (en) | 2012-05-25 | 2023-01-03 | Board of Regents on Behalf of Arizona State University | Microbiome markers and therapies for autism spectrum disorders |
US11819523B2 (en) | 2016-07-01 | 2023-11-21 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
-
1992
- 1992-04-24 JP JP4132042A patent/JP3047143B2/en not_active Expired - Fee Related
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9623056B2 (en) | 2000-07-20 | 2017-04-18 | Crestovo Llc | Probiotic recolonisation therapy |
US9408872B2 (en) | 2000-07-25 | 2016-08-09 | Crestovo Llc | Probiotic recolonisation therapy |
US9682108B2 (en) | 2000-07-25 | 2017-06-20 | Crestovo Llc | Probiotic recolonisation therapy |
US9962414B2 (en) | 2000-07-25 | 2018-05-08 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
US9867858B2 (en) | 2000-07-25 | 2018-01-16 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
US9789140B2 (en) | 2000-07-25 | 2017-10-17 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
US10772919B2 (en) | 2000-07-25 | 2020-09-15 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
US9737574B2 (en) | 2000-07-25 | 2017-08-22 | Crestovo Llc | Probiotic recolonisation therapy |
US9572841B2 (en) | 2000-07-25 | 2017-02-21 | Crestovo Llc | Probiotic recolonisation therapy |
US10369175B2 (en) | 2000-07-25 | 2019-08-06 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
US9901604B2 (en) | 2000-07-25 | 2018-02-27 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
US9610308B2 (en) | 2000-07-25 | 2017-04-04 | Crestovo Llc | Probiotic recolonisation therapy |
US9572842B2 (en) | 2000-07-25 | 2017-02-21 | Crestovo Llc | Probiotic recolonisation therapy |
US9468658B2 (en) | 2000-07-25 | 2016-10-18 | Crestovo Llc | Probiotic recolonisation therapy |
JP2002265372A (en) * | 2001-03-07 | 2002-09-18 | Shimizu Pharmaceutical Co Ltd | Intestinal tract-cleaning agent |
JP2005507407A (en) * | 2001-10-29 | 2005-03-17 | 清水製薬株式会社 | Intestinal cleansing preparation |
WO2003074061A1 (en) * | 2002-03-04 | 2003-09-12 | Borody Thomas J | Electrolyte purgative |
US8679549B2 (en) | 2002-03-04 | 2014-03-25 | Thomas Julius Borody | Electrolyte purgative |
US20110223252A1 (en) * | 2002-03-04 | 2011-09-15 | Thomas Julius Borody | Electrolyte purgative |
US7993682B2 (en) | 2002-03-04 | 2011-08-09 | Thomas Julius Borody | Electrolyte purgative |
JP2015038127A (en) * | 2009-06-03 | 2015-02-26 | アプタリス ファーマ ユーエス,インコーポレイテッド | L-sugar colon cleansing agent and uses thereof |
WO2011136336A1 (en) | 2010-04-30 | 2011-11-03 | 味の素株式会社 | Liquid preparation for oral administration which can be used in ct colonography, and composition for imaging of digestive tract |
US10463702B2 (en) | 2010-08-04 | 2019-11-05 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US10617724B2 (en) | 2010-08-04 | 2020-04-14 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US9962413B2 (en) | 2010-08-04 | 2018-05-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11890308B2 (en) | 2010-08-04 | 2024-02-06 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US10022406B2 (en) | 2010-08-04 | 2018-07-17 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11890307B2 (en) | 2010-08-04 | 2024-02-06 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US10064899B1 (en) | 2010-08-04 | 2018-09-04 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US10987385B2 (en) | 2010-08-04 | 2021-04-27 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11850269B2 (en) | 2010-08-04 | 2023-12-26 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11541080B2 (en) | 2010-08-04 | 2023-01-03 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11504403B2 (en) | 2010-08-04 | 2022-11-22 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US10278997B2 (en) | 2010-08-04 | 2019-05-07 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11491193B2 (en) | 2010-08-04 | 2022-11-08 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11207356B2 (en) | 2010-08-04 | 2021-12-28 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US10328107B2 (en) | 2010-08-04 | 2019-06-25 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11173183B2 (en) | 2010-08-04 | 2021-11-16 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US9308226B2 (en) | 2010-08-04 | 2016-04-12 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11129859B2 (en) | 2010-08-04 | 2021-09-28 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US10610551B2 (en) | 2010-08-04 | 2020-04-07 | Crestovo Holdings, Inc. | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11065284B2 (en) | 2010-08-04 | 2021-07-20 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US10675309B2 (en) | 2010-08-04 | 2020-06-09 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US10857188B2 (en) | 2010-08-04 | 2020-12-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US11103541B2 (en) | 2010-08-04 | 2021-08-31 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US10849937B2 (en) | 2010-08-04 | 2020-12-01 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
WO2012046847A1 (en) | 2010-10-08 | 2012-04-12 | 味の素株式会社 | Liquid preparation for oral administration which can be used in ct colonography, and composition for imaging digestive tract |
US10092573B2 (en) | 2010-12-13 | 2018-10-09 | Salix Pharmaceuticals, Inc. | Gastric and colonic formulations and methods for making and using them |
US10286011B2 (en) | 2011-03-09 | 2019-05-14 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
US10251914B2 (en) | 2011-03-09 | 2019-04-09 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
US9968638B2 (en) | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
US10028980B2 (en) | 2011-03-09 | 2018-07-24 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
US11801269B2 (en) | 2011-03-09 | 2023-10-31 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
US10286012B2 (en) | 2011-03-09 | 2019-05-14 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
US9649343B2 (en) | 2011-03-09 | 2017-05-16 | National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) | Compositions and methods for transplantation of colon microbiota |
US12084727B2 (en) | 2012-05-25 | 2024-09-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Microbiome markers and therapies for autism spectrum disorders |
US11542560B2 (en) | 2012-05-25 | 2023-01-03 | Board of Regents on Behalf of Arizona State University | Microbiome markers and therapies for autism spectrum disorders |
US11123377B2 (en) | 2015-05-14 | 2021-09-21 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
US12161678B2 (en) | 2015-05-14 | 2024-12-10 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
US9901603B2 (en) | 2015-05-14 | 2018-02-27 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
US10821138B2 (en) | 2015-05-14 | 2020-11-03 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
US11202808B2 (en) | 2015-05-22 | 2021-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US11357801B2 (en) | 2016-06-15 | 2022-06-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US11819523B2 (en) | 2016-07-01 | 2023-11-21 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US12186349B2 (en) | 2016-07-01 | 2025-01-07 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US11071759B2 (en) | 2016-08-03 | 2021-07-27 | Finch Therapeutics Holdings Llc | Methods for treating ulcerative colitis |
US10195235B2 (en) | 2016-08-03 | 2019-02-05 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
US10561690B2 (en) | 2016-08-03 | 2020-02-18 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
US11529375B2 (en) | 2017-04-05 | 2022-12-20 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
Also Published As
Publication number | Publication date |
---|---|
JP3047143B2 (en) | 2000-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3047143B2 (en) | Composition for intestinal lavage and intestinal lavage | |
US11241404B2 (en) | Method, composition and package for bowel cleansing | |
US6162464A (en) | Non-aqueous colonic purgative formulations | |
EP2233147B1 (en) | Salt solution for colon cleansing | |
EP0858326B1 (en) | Non-aqueous colonic purgative formulations | |
JP4535234B2 (en) | Intestinal cleansing preparation | |
US12239659B2 (en) | Methods of administering safe colon cleansing compositions | |
US20200352855A1 (en) | Colon Cleansing Composition and Methods of Using Same | |
JP2003183155A (en) | Pharmaceutical composition for washing intestinal tract | |
US20240325436A1 (en) | Safe Flavoring Composition to Improve Compliance in Colon Cleansing Compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080324 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 9 Free format text: PAYMENT UNTIL: 20090324 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 10 Free format text: PAYMENT UNTIL: 20100324 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 10 Free format text: PAYMENT UNTIL: 20100324 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 11 Free format text: PAYMENT UNTIL: 20110324 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120324 Year of fee payment: 12 |
|
LAPS | Cancellation because of no payment of annual fees |